Medinet Co
Kahoku · Founded 1995
About Medinet Co
Cancer immuno-cell therapy is an advanced medical practice, which requires advanced knowledge in biotechnology and molecular genetics, specific technical know-how, professional cell-engineers, dedicated-use facilities with advanced safety control, particular materials and a custom-made management system for cell-culturing schedule. However, it is difficult for medical institutions to meet all of these requirements on the financial and technical aspects, and only limited numbers of medical institutions, such as university hospitals, are able to fulfill such requirements. Such limited numbers of medical institutions perform the immuno-cell therapy to limited number of patients for research purpose only. Therefore, it seemed that the immuno-cell therapy had not been widely used in clinical practice. In order to make the immuno-cell therapy widely available to anyone who wish to receive, MEDINET created and started providing a comprehensive solution, which includes technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy, to medical institutions.
Company Facts
- Founded: 1995
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $4.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2015)
- Ticker: tyo:2370
- Website: medinet-inc.co.jpenglish
- Phone: +81454780041
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/medinet-co-3595141 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.